Cefuroxime 1mg/0.1ml solution for injection pre-filled syringes
Requires a prescription from a doctor or prescriber
Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Cefuroxime
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Cefuroxime
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(11)
Pyelonephritis (acute): antimicrobial prescribing (NG111)
Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)
Human and animal bites: antimicrobial prescribing (NG184)
Prostatitis (acute): antimicrobial prescribing (NG110)
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
Diverticular disease: diagnosis and management (NG147)
Cataracts in adults: management (NG77)
Urinary tract infection (lower): antimicrobial prescribing (NG109)
Otitis media (acute): antimicrobial prescribing (NG91)
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Pneumonia: diagnosis and management (NG250)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 11 · Randomised trials: 6 · 1976–2025
Showing the 50 most relevant studies, sorted by most relevant.
Randy C. Bowen, Andrew Xingyu Zhou, Sailaja Bondalapati, et al.
British Journal of Ophthalmology, 2018
- Moxifloxacin
- Anterior Chamber
- Anti-Bacterial Agents
Wang SS, Zhu BJ, Huang JN, et al.
2025
R. Dolor, D. Witsell, A. Hellkamp, et al.
JAMA, 2001
- Fluticasone
- Acute Disease
- Administration, Intranasal
R.N. Brogden, R.C. Heel, T.M. Speight, et al.
Drugs, 1979
- Aging
- Bacteria
- Bacteria, Anaerobic
N. Ahmed, Abdul Haseeb, A. Alamer, et al.
Antibiotics, 2022
Khaled A. Al-Abduljabbar, D. Stone
Middle East African Journal of Ophthalmology, 2017
Background: Endophthalmitis after cataract surgery is a rare but vision-threatening complication. Intracameral cefuroxime (ICC) has been reported to be effective at reducing the risk, but concerns regarding the risks associated with this intervention remain. Methods: Systematic review and synthesis of the literature on ICC, with a focus on the risks of therapy. Results: Level 2a evidence was found to support the use of cefuroxime in penicillin-allergic patients. Compounding or dilutional errors are associated with ocular toxicity, but the incidence and risk of this occurrence are unknown. Level 4 evidence supports interventions that reduce the risk of dilutional errors. The association of cefuroxime injection with toxic anterior segment syndrome (TASS) is not established; Level 5 evidence supports standard measures to reduce the incidence of TASS related to cefuroxime administration. Conclusion: Cefuroxime can be administered safely to penicillin-allergic patients, and steps should be taken to reduce the risk of compounding or dilutional errors to avoid negating the benefits of this intervention. Recommended practice patterns for endophthalmitis prophylaxis should consider the risks and benefits of ICC.
Abstract licence: CC BY-NC-SA
R. Linertová, R. Abreu-González, L. García-Pérez, et al.
Clinical Ophthalmology (Auckland, N.Z.), 2014
Liu T, Zhao R, Zhang H, et al.
2025
Mikkel Tøttrup, K. Søballe, B. Bibby, et al.
APMIS, 2019
Wei Fu, Zhiqiang Song, Liya Zhou, et al.
Digestive Diseases and Sciences, 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
194 found
Half-life
80 minutes
Mechanism
Cefuroxime, like the penicillins, is a beta-lactam antibiotic.
Food interactions
1 warning
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
37%
Half-life
80 minutes
Protein binding
50%
Metabolism
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 834 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins that transport this drug across cell membranes
PMID:15521010 PMID:18367661 PMID:19685173 PMID:26320580 PMID:7896779 PMID:8914574 PMID:9835627
Primarily responsible for the absorption of dietary di- and tripeptides from the small intestinal lumen (By similarity). Mediates transepithelial transport of muramyl and N-formylated bacterial dipeptides contributing to recognition of pathogenic bacteria by the mucosal immune system PMID:15521010 PMID:9835627
PMID:16434549 PMID:18367661 PMID:7756356
Transports neutral and anionic dipeptides with a proton to peptide stoichiometry of 2:1 or 3:1 (By similarity). In kidney, involved in the absorption of circulating di- and tripeptides from the glomerular filtrate .
PMID:7756356
Can also transport beta-lactam antibiotics, such as the aminocephalosporin cefadroxil, and other antiviral and anticancer drugs .
PMID:16434549
Transports the dipeptide-like aminopeptidase inhibitor bestatin (By similarity). Also able to transport carnosine .
PMID:31073693
Involved in innate immunity by promoting the detection of microbial pathogens by NOD-like receptors (NLRs) (By similarity).
Mediates transport of bacterial peptidoglycans across the plasma membrane or, in macrophages, the phagosome membrane: catalyzes the transport of certain bacterial peptidoglycans, such as muramyl dipeptide (MDP), the NOD2 ligand PMID:20406817
ATC S01AA27
ATC J01DC02
ATC J01RA03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Cefuroxime
Additional database identifiers
Drugs Product Database (DPD)
11118
Drugs Product Database (DPD)
8358
ChemSpider
4586393
BindingDB
50422689
PDB
KOV
ZINC
ZINC000003871978
GenBank Gene Database
BA000016
GenBank Protein Database
18145626
UniProt Accession
PBPA_CLOPE
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10920
GenAtlas
SLC15A1
GeneCards
SLC15A1
GenBank Gene Database
U13173
GenBank Protein Database
773588
Guide to Pharmacology
984
UniProt Accession
S15A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10921
GenAtlas
SLC15A2
GeneCards
SLC15A2
GenBank Gene Database
S78203
GenBank Protein Database
999213
Guide to Pharmacology
985
UniProt Accession
S15A2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q413728), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.